Fetal Development and Rh Immunization

Introduction to Rh Immunization

The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) recommend administration of Rh immune globulin to prevent potential alloimmunization in unsensitized Rh-negative women, even in early pregnancy, with limited evidence supporting its use in the first trimester but minimal harm from administration 1, 2

Rh immunization from first trimester threatened abortion is "exceedingly rare", but the theoretical risk and minimal harm from administration generally favor its use, according to ACOG and the American College of Emergency Physicians (ACEP) 2, 1
Fetal red blood cells display RhD antigens from as early as 6 weeks of gestation, creating potential for maternal sensitization even in early pregnancy, highlighting the importance of Rh immune globulin administration in Rh-negative women 1

A full dose (300 mcg) of Rh immune globulin is recommended for unsensitized Rh-negative women in cases of threatened abortion with continuing pregnancy, especially with "heavy" bleeding, associated abdominal pain, or when the event occurs near 12 weeks' gestation, as suggested by guidelines from ACEP and supported by ACOG and SMFM 2, 1
RhoGAM should be administered as a 300 mcg dose at 28 weeks' gestation, followed by another 300 mcg dose within 72 hours after delivery if the infant is Rh-positive, and for early pregnancy events before 12 weeks' gestation, a microdose (50 mcg) of RhoGAM is typically adequate, or a full dose (300 mcg) if the microdose is unavailable, as recommended by ACOG and SMFM 1

Only unsensitized Rh-negative women (those with a negative antibody screen) are eligible for RhoGAM to prevent Rh alloimmunization, while Rh-positive women do not require RhoGAM, and patients should be counseled on the implications of unknown blood type and potential risks of not receiving RhoGAM, as recommended by ACOG 1
In cases of supply shortages, the SMFM recommends prioritizing postpartum patients and antenatal patients at later gestational ages for RhoGAM administration, to maximize the prevention of Rh sensitization in those at highest risk, and in abortion care settings where RhD testing and RhoGAM administration would limit access to abortion care, the priority should be to complete the abortion, according to ACOG 1

Assessing gestational age is crucial, with higher risk near 12 weeks, making RhoGAM more strongly indicated, and evaluating bleeding severity is important, as heavy bleeding increases the risk of fetomaternal hemorrhage, making RhoGAM recommended 2
The presence of abdominal pain increases the risk of fetomaternal hemorrhage, making RhoGAM administration more necessary, as recommended by ACEP 2
Studies show that fetomaternal hemorrhage occurs in 48% of threatened abortions, emphasizing the importance of RhoGAM administration, and four cases of alloimmunization believed to be the result of threatened abortions have been reported, demonstrating the potential consequences of not administering RhoGAM 2

The evidence supporting the use of Rh immune globulin in the first trimester is limited, but the theoretical risk and minimal harm from administration generally favor its use, according to ACOG, and Rh immunization from first trimester threatened abortion is "exceedingly rare", according to ACEP and British authorities 1, 2
No randomized clinical trials have been conducted on pregnant Rh-negative women, highlighting the need for more research 2